APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology Biosimilars Market Outlook and Growth Opportunities 2026

21 December 2025191 pages

Choose your research edition.

Industry ResearchOncology Biosimilars Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Biosimilars Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Oncology Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Biosimilars Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Biosimilars Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Oncology Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology Biosimilars market include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oncology Biosimilars market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Biosimilars and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Biosimilars revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncology Biosimilars market.

Oncology Biosimilars Segment by Company

Teva Pharmaceutical Industries Ltd

Sandoz International

Pfizer

STADA Arzneimittel AG

Intas Pharmaceuticals

Dr. Reddy’s Laboratories

Celltrion

Biocon

BIOCAD

Apotex

Oncology Biosimilars Segment by Type

Hematopoietic Agents

Monoclonal Antibody

G-CSF

Others

Oncology Biosimilars Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacies

Oncology Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncology Biosimilars key companies, revenue, market share, and recent developments.

3. To split the Oncology Biosimilars breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncology Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Biosimilars industry.

Chapter 3: Detailed analysis of Oncology Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncology Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncology Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Biosimilars Industry Trends Table 2. Oncology Biosimilars Industry Drivers Table 3. Oncology Biosimilars Industry Opportunities and Challenges Table 4. Oncology Biosimilars Industry Restraints Table 5. Global Oncology Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Oncology Biosimilars Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncology Biosimilars Key Company Manufacturing Base & Headquarters Table 9. Global Oncology Biosimilars Company, Product Type & Application Table 10. Global Oncology Biosimilars Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hematopoietic Agents Table 15. Significant Companies of Monoclonal Antibody Table 16. Significant Companies of G-CSF Table 17. Significant Companies of Others Table 18. Global Oncology Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Oncology Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Oncology Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Oncology Biosimilars Sales Value Share by Type (2021-2026) Table 22. Global Oncology Biosimilars Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacy Table 24. Significant Companies of Online Pharmacy Table 25. Significant Companies of Retail Pharmacies Table 26. Global Oncology Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oncology Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Oncology Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Oncology Biosimilars Sales Value Share by Application (2021-2026) Table 30. Global Oncology Biosimilars Sales Value Share by Application (2027-2032) Table 31. Global Oncology Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oncology Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Oncology Biosimilars Sales Value Share by Region (2021-2026) Table 34. Global Oncology Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Oncology Biosimilars Sales Value Share by Region (2027-2032) Table 36. Global Oncology Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oncology Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Oncology Biosimilars Sales Value Market Share by Country (2021-2026) Table 39. Global Oncology Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Oncology Biosimilars Sales Value Market Share by Country (2027-2032) Table 41. Teva Pharmaceutical Industries Ltd Company Information Table 42. Teva Pharmaceutical Industries Ltd Business Overview Table 43. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio Table 45. Teva Pharmaceutical Industries Ltd Recent Development Table 46. Sandoz International Company Information Table 47. Sandoz International Business Overview Table 48. Sandoz International Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sandoz International Oncology Biosimilars Product Portfolio Table 50. Sandoz International Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pfizer Oncology Biosimilars Product Portfolio Table 55. Pfizer Recent Development Table 56. STADA Arzneimittel AG Company Information Table 57. STADA Arzneimittel AG Business Overview Table 58. STADA Arzneimittel AG Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. STADA Arzneimittel AG Oncology Biosimilars Product Portfolio Table 60. STADA Arzneimittel AG Recent Development Table 61. Intas Pharmaceuticals Company Information Table 62. Intas Pharmaceuticals Business Overview Table 63. Intas Pharmaceuticals Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Intas Pharmaceuticals Oncology Biosimilars Product Portfolio Table 65. Intas Pharmaceuticals Recent Development Table 66. Dr. Reddy’s Laboratories Company Information Table 67. Dr. Reddy’s Laboratories Business Overview Table 68. Dr. Reddy’s Laboratories Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio Table 70. Dr. Reddy’s Laboratories Recent Development Table 71. Celltrion Company Information Table 72. Celltrion Business Overview Table 73. Celltrion Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Celltrion Oncology Biosimilars Product Portfolio Table 75. Celltrion Recent Development Table 76. Biocon Company Information Table 77. Biocon Business Overview Table 78. Biocon Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biocon Oncology Biosimilars Product Portfolio Table 80. Biocon Recent Development Table 81. BIOCAD Company Information Table 82. BIOCAD Business Overview Table 83. BIOCAD Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. BIOCAD Oncology Biosimilars Product Portfolio Table 85. BIOCAD Recent Development Table 86. Apotex Company Information Table 87. Apotex Business Overview Table 88. Apotex Oncology Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Apotex Oncology Biosimilars Product Portfolio Table 90. Apotex Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Oncology Biosimilars Product Image Figure 2. Global Oncology Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hematopoietic Agents Image Figure 8. Monoclonal Antibody Image Figure 9. G-CSF Image Figure 10. Others Image Figure 11. Global Oncology Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Oncology Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Oncology Biosimilars Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacy Image Figure 15. Online Pharmacy Image Figure 16. Retail Pharmacies Image Figure 17. Global Oncology Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Oncology Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Oncology Biosimilars Sales Value Share by Application (2021-2032) Figure 20. Global Oncology Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Oncology Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Oncology Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 23. North America Oncology Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Oncology Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Oncology Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Oncology Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Oncology Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Oncology Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 29. South America Oncology Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Oncology Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Oncology Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Oncology Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Hematopoietic Agents
  • Monoclonal Antibody
  • G-CSF
  • Others
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacies
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International
  • Pfizer
  • STADA Arzneimittel AG
  • Intas Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • Celltrion
  • Biocon
  • BIOCAD
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncology Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncology Biosimilars Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncology Biosimilars Market Dynamics
  1. 2.1 Oncology Biosimilars Industry Trends
  2. 2.2 Oncology Biosimilars Industry Drivers
  3. 2.3 Oncology Biosimilars Industry Opportunities and Challenges
  4. 2.4 Oncology Biosimilars Industry Restraints
3 Oncology Biosimilars Market by Company
  1. 3.1 Global Oncology Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Biosimilars Company Ranking (2024-2026)
  4. 3.4 Global Oncology Biosimilars Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncology Biosimilars Company Product Type and Application
  6. 3.6 Global Oncology Biosimilars Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncology Biosimilars Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncology Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncology Biosimilars Market by Type
  1. 4.1 Oncology Biosimilars Type Introduction
  2. 4.1.1 Hematopoietic Agents
  3. 4.1.2 Monoclonal Antibody
  4. 4.1.3 G-CSF
  5. 4.1.4 Others
  6. 4.2 Global Oncology Biosimilars Sales Value by Type
  7. 4.2.1 Global Oncology Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oncology Biosimilars Sales Value by Type (2021-2032)
  9. 4.2.3 Global Oncology Biosimilars Sales Value Share by Type (2021-2032)
5 Oncology Biosimilars Market by Application
  1. 5.1 Oncology Biosimilars Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Oncology Biosimilars Sales Value by Application
  6. 5.2.1 Global Oncology Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oncology Biosimilars Sales Value by Application (2021-2032)
  8. 5.2.3 Global Oncology Biosimilars Sales Value Share by Application (2021-2032)
6 Oncology Biosimilars Regional Value Analysis
  1. 6.1 Global Oncology Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Biosimilars Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncology Biosimilars Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncology Biosimilars Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncology Biosimilars Sales Value (2021-2032)
  7. 6.3.2 North America Oncology Biosimilars Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncology Biosimilars Sales Value (2021-2032)
  10. 6.4.2 Europe Oncology Biosimilars Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncology Biosimilars Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncology Biosimilars Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncology Biosimilars Sales Value (2021-2032)
  16. 6.6.2 South America Oncology Biosimilars Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncology Biosimilars Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncology Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Oncology Biosimilars Country-level Value Analysis
  1. 7.1 Global Oncology Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Biosimilars Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncology Biosimilars Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncology Biosimilars Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncology Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncology Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncology Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Sandoz International
  8. 8.2.1 Sandoz International Company Information
  9. 8.2.2 Sandoz International Business Overview
  10. 8.2.3 Sandoz International Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz International Oncology Biosimilars Product Portfolio
  12. 8.2.5 Sandoz International Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Oncology Biosimilars Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 STADA Arzneimittel AG
  20. 8.4.1 STADA Arzneimittel AG Company Information
  21. 8.4.2 STADA Arzneimittel AG Business Overview
  22. 8.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  23. 8.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
  24. 8.4.5 STADA Arzneimittel AG Recent Developments
  25. 8.5 Intas Pharmaceuticals
  26. 8.5.1 Intas Pharmaceuticals Company Information
  27. 8.5.2 Intas Pharmaceuticals Business Overview
  28. 8.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
  30. 8.5.5 Intas Pharmaceuticals Recent Developments
  31. 8.6 Dr. Reddy’s Laboratories
  32. 8.6.1 Dr. Reddy’s Laboratories Company Information
  33. 8.6.2 Dr. Reddy’s Laboratories Business Overview
  34. 8.6.3 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
  36. 8.6.5 Dr. Reddy’s Laboratories Recent Developments
  37. 8.7 Celltrion
  38. 8.7.1 Celltrion Company Information
  39. 8.7.2 Celltrion Business Overview
  40. 8.7.3 Celltrion Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Celltrion Oncology Biosimilars Product Portfolio
  42. 8.7.5 Celltrion Recent Developments
  43. 8.8 Biocon
  44. 8.8.1 Biocon Company Information
  45. 8.8.2 Biocon Business Overview
  46. 8.8.3 Biocon Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biocon Oncology Biosimilars Product Portfolio
  48. 8.8.5 Biocon Recent Developments
  49. 8.9 BIOCAD
  50. 8.9.1 BIOCAD Company Information
  51. 8.9.2 BIOCAD Business Overview
  52. 8.9.3 BIOCAD Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BIOCAD Oncology Biosimilars Product Portfolio
  54. 8.9.5 BIOCAD Recent Developments
  55. 8.10 Apotex
  56. 8.10.1 Apotex Company Information
  57. 8.10.2 Apotex Business Overview
  58. 8.10.3 Apotex Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Apotex Oncology Biosimilars Product Portfolio
  60. 8.10.5 Apotex Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst